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Two new DTPA analogues, centrally (L1) and terminally (L2) functionalised with a 1,8-naphthalimide
chromophore, have been successfully prepared and fully characterized. Their Gd(III) complexes have also
been prepared and evaluated for their ability to act as dual modal contrast agents (MRI/OI). The highly
reproducible R1 relaxivity of L
1 (8.10  0.21 mM1 s1, 25 C and 30 MHz) is markedly higher than other
DTPA based contrast agents. The Gd(III) complexes of both L1 and L2 have been evaluated as
luminescence probes; the ligand based ﬂuorescence is not quenched upon complexation.Introduction
Diethylenetriaminepentaacetic acid (DTPA) is one of the most
well-known ligands and yields highly stable complexes with
hard metal ions. DTPA and its derivatives have been used in
a vast array of applications of medical interest, such as contrast
agents for medical imaging,1–5 radiotherapy, radiolabeling of
antibodies and peptides,6–9 radiopharmaceuticals and chelation
therapy.10–12 In particular, the gadolinium complex of DTPA has
long been successful as a contrast agent, ever since it was
approved by the FDA in 1988.13
However, the perceived disadvantage of Gd-DTPA is that the
chelate has been prepared in hypertonic solutions, where issues
related to high osmolarity become signicant. The investiga-
tions have been intensied on the synthesis and characteristics
of novel Gd(III) complexes to minimize toxicity issues while
ensuring relaxation rate enhancement. The biocompatibility of
the multidentate DTPA derivatives makes it an ideal choice.
DTPA also oﬀers the advantage of incorporating a well-dened
structural molecule, to a chosen biological molecule (which
could be proteins in the blood, antibodies or similar biological
macromolecules) due to their multidentate feature.
Several strategies have been utilised in the synthesis of
substituted DTPA frameworks. These approaches include (i) the
attachment of substituents via an amide linkage to a carbox-
ylate group of the preformed DTPA ligand or (ii) the direct
bonding of the substituent to the diethyltriamine core.
The attachment of substituents to DTPA via an amide link is
a useful strategy as it is a simple and convenient method that
can give compounds in high yields and good purity. There aren Building, Park Place, CF10 3AT, Cardiﬀ,
tion (ESI) available. See DOI:
hemistry 2017numerous reportedmethods to carry this reaction out.14–25 Some
methods involve the use of coupling reagents to couple the
amine containing substituent to the DTPA,26 though the
simplest method involves the conversion of DTPA to the
bisanhydride analogue, which may then be directly reacted with
a suitable amine.27–29 While this is an extremely eﬀective
approach, the method has some drawbacks in that, despite
reports of the synthesis on mono substituted analogues,30 such
reactions are diﬃcult and oen an impure product is obtained
which requires extensive eﬀorts to purify. Secondly, the
substituent is bound by an amide group which results in a lower
thermodynamic stability and potentially increased toxicity.
For the direct attachment of a moiety to the diethyltriamine
framework, typically, (i) a single moiety may be attached to the
central nitrogen,31 (ii) two identical moieties may be attached to
the terminal nitrogens32,33 or (iii) the ethylene spacers of the
framework may be substituted.34,35
The dialkylation of a primary amine using di-tert-butyl 2,20-
((2-bromoethyl)azanediyl)diacetate (2) will result in the forma-
tion of a DTPA framework. Amino acids, such as L-cysteine,36
L-phenylalanine,37 L-glutamic acid and lysine,38 were previously
utilised as primary amines in the construction of such DTPA
analogues. In addition, there is a further report of an aliphatic
alkyl amine31 being used as the central moiety of a constructed
DTPA-like ligand.
Further, bi-substituted DTPA analogues have been con-
structed from diethylene triamine starting material using two
equivalents of 2,20-bipyridine-5-carboxaldehyde,32 while Artali
et al.33 reported an analogous approach to incorporate the
2-hydroxymethyl pyridine group. However, it should be noted,
that reports of mono substituted terminal nitrogens of a DTPA
frame-work are scarce.39–42
Furthermore, reproducible relaxivity measurements re-
ported for L1 in this report is on the higher side. Most of the
polyamino polycarboxylate scaﬀolds used as commercialRSC Adv., 2017, 7, 38463–38470 | 38463
Fig. 1 Schematic representation of commercial contrast agents and
some selected C4-substitued DTPA analogues.
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View Article Onlinecontrast agents have relaxivities in the range of 4–5 mM1 s1
(at 30 MHz, 25 C). Acyclic DTPA analogues reported to date also
have comparable relaxivities to those of commercially available
contrast agents based on polyamino polycarboxylates (Fig. 1).
Exceptionally higher relaxivities were reported by Raymond
et al.43 for their HOPO based contrast agents (7–13 mM1 s1).
Very recently, piperadine based rigidied DTPA analogues have
been reported to exhibit relaxivity in the range of
5.2–6.0 mM1 s1 (at 20 MHz, 25 C).DTPA based amide derivatives bearing chromophores: a novel
approach
Herein we report the synthesis of two potential dual mode
imaging agents. The synthesised ligand will contain a single
organic luminescent moiety which has been directly alkylated to
the nitrogen atom of a diethylene triamine. Two possibilities
exist, with the lumophore being alkylated to the central
nitrogen or to one of the two terminal nitrogens. The rst
approach utilises 2 for the dialkylation of the appropriate
amine. This approach will produce a symmetric ligand
(Fig. 2, type A). The appropriate choice of amine will yield
a ligand with a lumophore bonded to the central amine. The
second approach utilises a monosubstituted diethylene tri-
amine species which may be alkylated to yield anFig. 2 Depicting the novel chromophore bearing centrally substituted
and terminally substituted DTPA analogues.
38464 | RSC Adv., 2017, 7, 38463–38470asymmetrically monosubstituted DTPA ligand (type B). The
lumophore is incorporated into these ligand frameworks as the
naphthalimide moiety (Fig. 2).
Experimental
General experimental
Reagents were obtained from commercial sources and used as
received unless otherwise noted. Solvents were dried and puri-
ed under N2 by using standard methods and were distilled
immediately before use, specically dimethlyformamide, was
distilled using anhydrous calcium hydride. All compounds were
prepared under N2 unless otherwise mentioned. The NMR
spectra were obtained using a Bruker ARX 400 at 20 C in CDCl3
unless otherwise noted. Mass spectra were performed on
a micromass platform II system, operating in ow injection
analysis mode, with the electrospray method. Infrared spectra
were recorded with a JASCO FTIR-410 spectrometer, between
4000 and 500 cm1 as KBr pellets. UV/vis spectra and
measurements were recorded with a JASCO V-570
spectrophotometer.
The synthesis of 2-(2-aminoethyl)-1H-benzo[de]isoquinoline-
1,3(2H)-dione (3) was carried out following the reported litera-
ture procedure.36b
Luminescence measurements
The photophysical data for luminescence were obtained on
a JobinYvon-Horiba Fluorolog spectrometer tted with a JYTBX
picosecond photo detection module. Water insoluble DTPA
analogues were dissolved in chloroform and as required water-
soluble lanthanide complexes of DTPA analogues were dis-
solved in water. Although all of the new ligands and complexes
prepared were air stable both in the solid state and solution,
some of the ligands and complexes were found to be hygro-
scopic, when le in the open atmosphere for prolonged periods
of time.
1H NMRD acquisition
The 1/T1 NMRD proles were obtained on a Stellar Spin master
FFC-2000 relaxometer, typically covering a continuum of
magnetic elds from 2.4  104 to 0.72 T (corresponding to
a proton Larmor frequency range 0.01–30 MHz). A Spin master
Variable Temperature Controller (VCT) allowed the setting and
monitoring of the sample temperature at two diﬀerent
temperatures, 25 C and 37 C with a resolution up to 0.1 C.
Each sample was allowed to acclimatise to the desired
temperature for 15 minutes prior to data collection. The
reproducibility in T1 measurements was within 1%.
Synthesis of di-tert-butyl 2,20-((2-hydroxyethyl)azanediyl)
diacetate (1).36 The procedure as reported by Choi et al.36 was
used, except for slight modications. To tert-butyl bromoacetate
(17.02 ml, 116 mmol) dissolved in DMF (30 ml), potassium
carbonate (12.51 g, 90 mmol) was added. The reaction mixture
was cooled down to 0 C and ethanolamine (2.98ml, 49.4 mmol)
added dropwise for 5 min. The reaction mixture was stirred at
0 C for 30 min and then allowed to stir overnight at roomThis journal is © The Royal Society of Chemistry 2017
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View Article Onlinetemperature. Aer an addition of concentrated NaHCO3
(100 ml) and diethyl ether (150 ml), the organic layer was
separated and washed with concentrated NaHCO3 (50 ml) and
subsequently with brine (200 ml). The solvent was removed
under reduced pressure to yield the product as pale yellow solid.
Yield 14.2 g, 42%; characterisation data was similar to that
previously reported.36
Synthesis of di-tert-butyl 2,20-((2-bromoethyl)azanediyl)
diacetate (2).38 PPh3 (4.34 g, 16.55 mmol) was dissolved in
dichloromethane (25 ml), and NBS (2.99 g, 16.80 mmol) was
added portion wise. The mixture was allowed to stir at 0 C
(until the colour of the solution changes from yellow to light
brown). The mixture was added to a dichloromethane (25 ml)
solution of 1 (6.00 g, 20.74 mmol), dropwise at 0 C. The reac-
tion mixture was allowed to stir overnight. The solvent was
removed and to the crude product was added diethyl ether
(30 ml). The sticky solid was triturated and ltered. The ltrate
was evaporated and the crude product was ash chromato-
graphed (hexane : diethyl ether, 5 : 1). The product was ob-
tained as a colourless oil. Yield 2.0 g, 28%; 1H NMR (400 MHz;
CDCl3) dH (ppm) 3.45 (s, 4H, NCH2COOC (CH3)3), 3.41 (t, 2H,
J ¼ 7.4 Hz, BrCH2), 3.11 (t, 2H, J ¼ 7.4 Hz, BrCH2CH2N), 1.44
(s, 18H, COOC (CH3)3).
Synthesis of tetra-tert-butyl 2,20,200,2000-((((2-(1,3-dioxo-1H
benzo[de]isoquinolin-2(3H)-yl)ethyl)azanediyl)bis(ethane-2,1-
diyl))bis(azanetriyl))tetraacetate (4). To bromide 2 (1.00 g,
2.84 mmol) was added K2CO3 (3.40 g, 25 mmol) and previously
synthesized 3 (0.34 g, 1.42 mmol). DMF was added and the
reaction mixture was gently heated to 65 C and stirred over-
night. The solvent was removed. The crude product was
puried by ash chromatography (5% MeOH : DCM mixture).
The pure product was obtained as a yellow oil. Yield 0.62 g,
54%; 1H NMR (400 MHz, CDCl3): dH (ppm) 8.50 (d, 2H,
J ¼ 7.27 Hz, ArH), 8.10 (d, 2H, J ¼ 8.13 Hz, ArH), 7.70 (m, 2H,
ArH), 4.30 (m, 4H), 3.40 (m, 8H), 2.85 (br s, 8H), 1.40 (s, 36H);
13C NMR (400 MHz; D2O): dC 170.7, 163.4, 133.2, 130.6, 127.2,
121.5, 80.9, 45.4, 52.4, 55.1, 27.1; IR (KBr disc) (cm1): 3440(br),
2977(s), 2931(w), 1736(s), 1702(w), 1661(vs), 1628(w), 1591(s);
ESI-MS (+ion): found m/z 783.4578, calc. 783.4544 for [(4) H]+.
2,20,200,2000-((((2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)
ethyl)azanediyl)bis(ethane-2,1 diyl))bis(azanetriyl))tetraacetic
acid, (L1). To compound 4 (0.12 g, 0.153 mmol) was added 2 M
HCl (10 ml, 323 mmol) and the reaction mixture was reuxed
for 2 h. The solvent was removed under high vacuum to give the
product as pale yellow solid. Yield 0.072 g, 84%; 1H NMR
(400 MHz, D2O) dH (ppm) 8.00 (d, 2H, J ¼ 6.79 Hz), 7.92 (d, 2H,
J ¼ 8.41 Hz), 7.40 (t, 2H, J ¼ 6.94 Hz), 3.7 (m, 4H), 3.40 (s, 8H),
2.90 (m, 4H), 2.80 (m, 4H); 13C NMR (400 Hz, D2O) dC 172.2,
168.7, 135.4, 135.6, 131.8, 131.6, 130.8, 127.1, 126.6, 119.9, 55.8,
55.3, 52.3, 50.8, 37.0; IR (KBr disc) (cm1): 3430(br), 2963(w),
1695(s), 1655(vs), 1625(w), 1588(s); ESI-MS (ion): found m/z
557.16, calc. 557.00 for [(L1) H].Complexation of L1 with Gd(III) chloride
L1 (28 mg, 0.05 mmol) and GdCl3. 6H2O (18.0 mg 0.05 mmol)
were added to two diﬀerent vials. The ligand was dissolved inThis journal is © The Royal Society of Chemistry 2017ethanol 10 ml, and heated slightly to ensure complete dissolu-
tion. Then GdCl3 was dissolved in distilled H2O, and again
heated to ensure complete dissolution. Thereaer the vial
containing the metal salt solution was continuously stirred, and
the ligand solution was added dropwise. The instantaneous
formation of the precipitate was observed. Aer the complete
addition of the ligand to the metal, the mixture was stirred for
two days in the dark. The solvent was evaporated to give a yellow
precipitate of the complex. Yield 84%; IR (KBr disc, cm1):
3425(br), 1729(w), 1625(s), 1408(s); ESI-MS (ion): found m/z
712.0898, calc. 712.0890 for [(L1) Gd]. UV/vis [lmax, nm
(3, M1 cm1)] in H2O: 235(17 658), 274(4128), 344(6279). The
complexation reaction of L1 with Eu(III) chloride, Yb(III) chloride
and Nd(III) chloride were carried out as described for complex-
ation with Gadolinium chloride. However in the case of Nd(III)
chloride it had to be dissolved in DMF, instead of water.
Synthesis of 2-(2-((2-((2-aminoethyl)amino)ethyl)amino)
ethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (5). To 1,8-
naphthalic anhydride (1.00 g, 5.05 mmol) was added triethyle-
netetramine (4.50 ml, 30 mmol) and allowed it to reux over-
night. Solvent was removed by distillation. The crude product
was dissolved in dichloromethane and ltered. The ltrate was
evaporated. To purify further, the product was extracted into
toluene; the toluene washings (3  30 ml) were evaporated to
dryness and the product was obtained as a dark brown sticky
solid. Yield 0.7 g, 42%; 1H NMR (D2O, 400 Hz) dH (ppm) 8.50
(d, 2H, J ¼ 8.53 Hz, ArH), 8.10 (d, 2H, J ¼ 8.14 Hz, ArH), 7.70
(t, 2H, J ¼ 8.00 Hz, ArH), 4.35 (t, 2H, J ¼ 5.8 Hz, NCH2CH2NH),
2.95 (t, 4H, J ¼ 12 Hz, NCH2CH2NH), 2.80 (t, 2H, J ¼ 8.00 Hz,
NHCH2CH2NH), 2.7 (t, 2H, J ¼ 10 Hz, NHCH2CH2NH2), 2.6 (m,
4H); IR (KBr disc) (cm1): 3416(br), 2964(s), 2822(w), 1699(s),
1660(vs), 1625(w), 1590(s), 1439(s); ESI-MS (+ion): found m/z
349.15, calc. 349.17 for [(5) H]+.
Synthesis of di-tert-butyl 2,20-((2-((2-(tert-butoxy)-2-
oxoethyl)(2-((2-(tert-butoxy)-2-oxoethyl)(2-(1,3-dioxo-1H-benzo
[de]isoquinolin-2(3H)-yl)ethyl)amino)ethyl)amino)ethyl)azane-
diyl)diacetate (6). To tert-butyl bromoacetate (2.27 ml,
15.58 mmol) was added K2CO3 (10.00 g, 72.46 mmol) and
previously synthesized 5 (1.01 g, 3.00 mmol). Aer the addition
of DMF (20 ml), the reaction mixture was gently heated up to
65 C and allowed to stir overnight. Then the solvent was
removed. The crude product was puried by ash chromatog-
raphy the material (90 : 10 dichloromethane/methanol); the
product was obtained from the eluents by evaporation of the
solvent mixture. Yield 0.25 g, 20%; 1H NMR (CDCl3, 400 MHz)
dH 8.50 (d, 2H, J ¼ 7.13, ArHa), 8.10 (d, 2H, J ¼ 7.98, ArHc), 7.70
(t, 2H, J ¼ 7.73, ArHb), 4.2 (m, 2H), 3.4 (s, 8H), 2.9 (m, 2H), 2.8
(m, 2H), 2.7 (m, 2H), 2.6 (m, 4H), 1.4 (s, 36H); 13C NMR
(400 MHz, CDCl3): dC 169.0, 163.1, 132.8, 130.6, 130.2, 125.9,
121.7, 79.8, 55.0, 54.8, 51.9, 51.8, 50.9, 37.2, 27.1, 27.0, 27.1,
26.9; IR (KBr disc) (cm1): 3467(br), 2973(s), 2360(s), 1733(vs),
1648(s), 1595(s); ESI-MS (+ion): found m/z 783.45, calc. 783.45
for [(6) H]+.
Synthesis of 2,20-((2-((carboxymethyl)(2-((carboxymethyl)(2-
(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)ethyl)amino)ethyl)
amino)ethyl)azanediyl)diacetic acid (L2). The compound 6
(0.12 g, 0.15 mmol) was added to a round bottom ask and 2 MRSC Adv., 2017, 7, 38463–38470 | 38465
Fig. 3 Schematic representation of the synthesis of symmetric ligand
(L1).
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View Article OnlineHCl (10 ml) was added and the reactionmixture was reuxed for
2 h. Aer 2 h, the solvent was removed in vacuo. Yield 0.07 g,
58%; 1H NMR (400 MHz, D2O) dH (ppm) 8.00 (dd, 4H, J¼ 8.8 Hz,
other constant not determined, ArHa,c) 7.45 (t, 2H, J ¼ 26 Hz,
ArHb), 3.00–4.25 (m, 20H); IR (KBr disc) (cm
1): 3428(br),
29649(w), 2532(w), 1738(s), 1702(w), 1654(s), 1590(w); ESI-MS
(+ion): found m/z 559.2057, calc. 559.2040 for [(L2) H]+.
Complexation of L2 with Gd(III) chloride
Complexation was carried out in a similar manner described for
L1. Yield 85%; IR (KBr disc) (cm1): 3404(br), 1728(w), 1644(s),
1408(s); ESI-MS (ion): found m/z 714.23, calc. 714.11 for [(L2)
Gd]. UV/vis [lmax, nm (3M, M
1 cm1)] in H2O: 235(6752),
267(1679), 345(2309).
Results and discussion
General synthesis
Ligand design and synthesis of DTPA analogues
Symmetric ligand, L1
(a) Synthesis of 2. The synthesis of 2 following the reported
procedure gave low yields in our hands. However a small
modication to the procedure allowed us to synthesise 2 in
improved yield and purity. The phosphonium bromide was rst
prepared by the portionwise addition of NBS to the dissolved
solution of triphenyl phosphine in dichloromethane (successful
preparation of the phosphonium bromide is indicated by the
formation of sticky, semi solid-triphenylphosphine oxide).44
The prepared phosphonium bromide was then added dropwise
to the solution of 1 in dichloromethane. The rest of the proce-
dure was followed as reported by Anelli et al.38
(b) Alkylation of 3. Initially, compound 3 was added together
with bromide 2 in the stoichiometric ratio of 1 : 2 in anhydrous
DMF (Fig. 3). The reaction mixture was heated to 65 C and
allowed to reux for 48 h. Purication by thin layer chroma-
tography (TLC) was carried out with 5% methanol/
dichloromethane used as the eluent. The puried protected
form of the ligand thus obtained, subsequently underwent
deprotection by reuxing the protected ligand in 2 M HCl for
two hours according to the procedure reported by Vogt et al.30
The ligand L1 was isolated in good yield (90%).
Asymmetric ligand, L2. Triethylenetetramine (TRIEN) was
reacted with 1,8-naphthalic anhydride to produce the new
ligand 5. The 1H NMR spectrum of the crude mixture conrmed
the reaction had occurred with a signicant change to the
aliphatic protons consistent with a lowering of the symmetry of
the TRIEN core.
The alkylation of this product was carried out using the same
conditions as for the symmetric ligand, using stoichiometric
amounts of alkylation agent (Fig. 4). With resulting low yields,
a 1 : 5 molar ratio was used to try to improve the amount of
product and its purity, however 1H NMR still indicated an the
excess of compound 5. The reaction time was varied from 2 to 7
days, with little eﬀect on the yield. Similarly, increasing the
reaction temperature did not appreciably improve the yield.
Purication of the reaction mixture was carried out by38466 | RSC Adv., 2017, 7, 38463–38470chromatography (95 : 5 dichloromethane/methanol) giving
a yield of <20% isolated product.
Characterisation
1H and 13C NMR. The puried, protected and deprotected
forms of L1 and L2 were characterized by NMR spectroscopy.
Each compound gave a spectrum consistent with the proposed
structure. Chemical shis were assigned by comparison to
previously publish data.15,35,45
In 4, the four equivalent pendant carboxylate CH2-protons
appear as a broad singlet at 2.85 ppm indicating a strong upeld
shi due to alkylation and the CH2-protons are subsequently
shied to 3.40 ppm upon deprotection, in L1. Curiously,
a similar singlet was visible in the protected form of L2 (6) at
3.40 ppm, suggesting a less intensive inductive eﬀect by adja-
cent t-butyl groups.
IR spectroscopy. The infrared spectrum of both L1 and L2
exhibited strong absorption bands in the region of 3300–
3400 cm1 and 1650 cm1, corresponding to NH and CO
stretching vibrations, respectively (Table 1). Upon complexation
with gadolinium, the CO stretching vibrations of the amideThis journal is © The Royal Society of Chemistry 2017
Fig. 4 Schematic representation of the synthesis of asymmetric ligand
(L2).
Table 1 A comparison of frequencies (cm1) obtained for diﬀerent
vibrational modes of IR for the symmetric and asymmetric ligands
along with their starting materials and Gd(III) complexed formsa
Compound
n(C]O)
amide
n(C]O)
ester
n(C]O)
acid n(O–H) n(N–H)
2 1737
3 1662 3346
4 1654 1739 3314
L1 1655 1695 3429
Gd-L1 1623 1729 3424
1a 1731
5 1659 3416
6 1648 1732 3414
L2 1654 1702 3427
Gd-L2 1644 1728 3403
a 1a–tert-butyl bromoacetate.
Table 2 A comparison of relaxivities of commercially available MRI
contrast agents with L1
Ligand
Temp.
(C)
1H freq.
(MHz)
r1
(s1 mM1) Ref.
GdCl3_1 mM (free) 25 30 12.64
Gd(III)-L1 (complex) 25 30 8.10
Magnevist® 37 20 3.80 49
Omniscan®a 37 20 3.80 50
Eovist® 37 64 7.14 49
Multihance® 39 20 5.35 51
Ablavar™ 37 64 5.20 49
a Gd–DTPA-BMA.
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View Article Onlineattracts a red shi for both L1 and L2. However, while L1
exhibited a signicant red shi (ca. 30 cm1), L2 exhibited
a smaller shi (ca. 10 cm1). This may be attributed to weak
coordination of the amide oxygen to the metal ion, in contrast
to L1.
Mass spectrometry. The molecular ions for the Gd(III)
complexes of both L1 and L2 were visible in the mass spectra of
these respective ligands. In the ESI mass spectra acquired in the
negative mode indicated molecular ion peak of L1 at 557.16.
However, the most intense peak for L2 at 559.20 was found in
the positive mode.
Evaluation of DTPA analogues
Both centrally and terminally substituted DTPA analogues have
been exploited for their use in MRI applications.47 As of today,
most of the DTPA analogues tested and recognized as contrast
agents belong to the terminally-substituted category,48 but
investigations related to direct substitution of a chromophoric
moiety in the central nitrogen, remains scarce.13,44,46
Similarly, terminally substituted and C-substituted (on
ethylenic carbon) analogues comprise the majority of DTPA
analogues (including the commercially available contrast
agents, namely Eovist® and Multihance®). The relaxivity of the
new contrast agent based on L1 at relevant magnetic eld
strengths (8.10 mM1 s1 at 30 MHz and 25 C) is considerably
higher than that of the commercially available contrast agentsThis journal is © The Royal Society of Chemistry 2017Eovist®, Multihance® and Ablavar™ (previously known as
Vasovist® or MS-325) (Table 2).
In contrast to L1, the poor yield of L2 limited analogous
investigations of relaxivity.
DTPA analogues have also been exploited for luminescence
based applications. Examples include DTPA functionalised with
Carbostyril-124 (CS-124),52 CS-124 covalently bound to trimeth-
oprim,53 amine functionalised reactive groups such as iso-
thiocynates and thiol-reactive groups such as pridyldithiol,
maleimide, methanethiosulfonate and haloacetyl acetamide.54
Further, DTPA analogues have been investigated for their usage
in dissociation enhanced uoroimmunoassay (DELFIA).55Fluorescence on binding with lanthanides
In the following experiments we have not concerned ourselves
with the lanthanide phosphorescence spectrum. Instead, we are
interested by changes in the organic uorescence spectrum on
lanthanide binding. Primarily, we wish to show that the organic
lumophore is not totally quenched upon lanthanide binding
and any shi in the spectrum is small.
The emission proles of the protected form of the symmetric
ligand, 4, compared to its deprotected form, L1, exhibited only
slight diﬀerences, with only a slight red shi occurring in the
excitation wavelength. The formation of the gadoliniumRSC Adv., 2017, 7, 38463–38470 | 38467
Table 3 Spectroscopic properties of the symmetric ligand in its pro-
tected, deprotected and complexed forms, measured in CHCl3$H2O
and lex, lem, are excitation maxima, emission maxima and ﬂuorescent
yield respectively
Compound lex (nm) lem (nm) A 3
4a 336 383
L1 345 396
Gd-L1 345 395 235 6752
6a 335 383
L2 345 396
Gd-L2 345 396 235 17 658
a Water insoluble ligand, dissolved in chloroform.
Fig. 6 Luminescence spectra of Gd complex of asymmetric ligand
(Gd-L2) (excitation at 345 nm and emission at 396 nm).
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View Article Onlinecomplex, conrmed through the use of xylenol orange, results
in little change to the luminescence spectrum, with no diﬀer-
ence noted in the excitation wavelength and no change
observed in the emission spectrum, compared to L1 (Table 3
and Fig. 5). Similarly, the formation of the gadolinium complex
of L2 did not result in a signicant quenching of the lumines-
cence signal of the free ligand (Fig. 6), nor did it shi the
excitation and emission wavelengths to a signicant degree.
Clearly, the luminescence spectroscopy indicates that it may
be possible to utilize the gadolinium complexes of L1 and L2 as
luminescent probes, though their eﬃciency in such an appli-
cation remains to be determined.Relaxivity measurements
2,20,200,2000-((((2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)
ethyl)azanediyl)bis(ethane-2,1 diyl))bis(azanetriyl))tetra acetic
acid (L1). Fig. 7 depicts the 1H NMRD prole of the Gd(III)
complex of L1. Reproducibility of the results was ensured by
repeating the whole synthesis and repeating the measurements
under the same conditions. Long term reproducibility of relax-
ivity of the same sample, under identical experimental conditions
over an extended period of time (4 months) was also established.
Long term stability of the same sample in solution was also
corroborated by testing with xylenol orange indicator indicating
the absence of free Gd(III) in the sample. The relaxivity of a 1 mM
concentration solution of the complex is high compared to other
standard DTPA based complexes (8.10  0.21 mM1 s1 at
30MHz, 25 C). The comparable relaxivity data is given in Table 2.Fig. 5 Luminescence spectra of Gd complex of symmetric ligand
(Gd-L1) (excitation at 345 nm and emission at 395 nm).
38468 | RSC Adv., 2017, 7, 38463–38470The enhancement relaxivity of water protons results from
dipolar interaction of the electron magnetic moment of the
paramagnetic metal ion with that of the nuclear magnetic
moment of solvent nuclei. This interaction comprises contri-
butions from water molecules that belong to the inner, outer
and secondary coordination spheres. It has been reported, that
for low molecular weight Gd(III) based mono aqua hydrophilic
complexes, the inner-sphere and outer-sphere contributions are
comparable, giving rise to relaxivity values which lie in the
range of 4–5 mM1 s1 at 25 C and 20 MHz,1 while the
contribution from secondary-sphere water molecules has not
been as extensively studied.56
However, the observed relaxivity was very much on the
higher side for Gd(III)-L1 (8.65 mM1 s1) could be related to the
concentration of the contrast agent by the following equation.
R1obs ¼ R1W + [Gd(III)-L1]r1p
where R1W represents the relaxivity of pure water
(0.55 mM1 s1 in 30 MHz, 25 C). Therefore the true relaxivity
of Gd(III)-L1 is 8.10 mM1 s1, which is still relatively higher
than the relaxivity of the commercial contrast agent, ‘Eovist’. As
per the equation below, relaxivity is highly dependent on the
number of water molecules bound to the metal centre (q) and
their rate of exchange with the bulk water (sM).
(1/T1) ¼ qPm[1/(T1m + sM)]
where 1/T1 is the longitudinal relaxation rate and Pm is the mole
fraction of water coordinated to the metal centre. AllFig. 7 1H NMRD Proﬁle of Gd(III)-L1 complex obtained across ﬁeld
strengths ranging from 0.01–30 MHz (expressed in logarithmic scale
for purpose of clarity) at 25 C.
This journal is © The Royal Society of Chemistry 2017
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View Article Onlinecommercial contrast agents possess q ¼ 1, which results in
comparatively low relaxivity. Gd(III) complexes possessing high
relaxivity with high q values (q ¼ 2) have been reported in the
past for acylic aminocarboxylate compounds as well.57 However,
such an approach is problematic due to decreased complex
stability and hence increased agent toxicity. In addition, higher
q values may lead to the ready formation of ternary complexes in
biological media and ultimately lead to lower relaxivity in vivo.Conclusions
Two new DTPA analogues have been synthesized. A chromo-
phore bearing, central nitrogen substituted, DTPA analogue has
been synthesized distinguishing these new ligands from
commercial contrast agents and incorporating the naph-
thalimide moiety into the DTPA backbone. The Gd(III)
complexes exhibit ligand-based luminescence and Gd-L1 has
a relatively high relaxivity. Further investigations are necessary
to determine if these reagents are toxic and the relaxivity is
maintained in vivo.Conﬂicts of interest
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